Clinical Trials

73 enrolled

Lymphoma, Follicular

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

237 enrolled

Lymphoma, Follicular

NCT00843882 2026-03-18

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01522976 2026-03-18

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

282 enrolled 11 charts

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01711554 2026-03-18

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

27 enrolled

CNS

Neuroblastoma

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

70 enrolled

Multiple Myeloma

NCT02160015 2026-03-17

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04133636 2026-03-17

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT04404283 2026-03-17

ECHELON-3

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05257083 2026-03-17

CARTITUDE-6

759 enrolled

Multiple Myeloma

NCT06353022 2026-03-17

IFm2022-01

103 enrolled

Multiple Myeloma

NCT05690984 2026-03-16

EMAT

30 enrolled

Multiple Myeloma, Neoplasm, Residual

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

19 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT03901963 2026-03-13

AURIGA

200 enrolled 12 charts

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

43 enrolled

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04802356 2026-03-05

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

50 enrolled

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

79 enrolled

Multiple Myeloma

NCT03070327 2026-03-04

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

20 enrolled

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00602641 2026-03-03

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Multiple Myeloma

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-03-03

EPCORE DLBCL-3

111 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT00378105 2026-02-24

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

68 enrolled 9 charts

Multiple Myeloma

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

46 enrolled 15 charts

Multiple Myeloma

NCT05888493 2026-02-20

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT01297764 2026-02-19

QUAD

17 enrolled

Multiple Myeloma

NCT02446236 2026-02-19

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT06723457 2026-02-17

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

34 enrolled

Lymphoma, B-Cell

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT04876248 2026-02-05

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

4 enrolled

Multiple Myeloma

NCT04712097 2026-02-04

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

662 enrolled

Multiple Myeloma

NCT04113018 2026-02-03

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

39 enrolled 16 charts

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT04430894 2026-01-29

KRDI in Transplant-Eligible MM

50 enrolled 20 charts

Multiple Myeloma

NCT01446133 2026-01-27

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 1 FDA

Multiple Myeloma

NCT05222555 2026-01-16

MINDway

53 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT04653246 2025-12-23

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

52 enrolled

Multiple Myeloma

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 1 FDA